Loading
A phase 2/3 trial of sugemalimab in lung cancer, run by Sun Yat-sen University, now recruiting.
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT is a phase 2/3, randomised interventional study registered as NCT05623267 by Sun Yat-sen University, with a registry enrolment figure of 346 participants, started 2023-07-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: Sugemalimab; Placebo. Conditions listed: Limited Stage Small Cell Lung Cancer. Primary outcome: Progress Free Survival(PFS). Lung eligibility wording from the registry: "2、Histologically or cytologically confirmed small cell lung cancer". Sites: China. No results are recorded here; the registry entry is the source.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.